Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli.
We evaluated the pharmacokinetics of amoxicillin-sulbactam (AMX-SUL), a novel drug combination, and its pharmacodynamics against Escherichia coli in 12 volunteers receiving a single oral dose (1, 000 mg). Peak serum bactericidal and urine inhibitory activities in most volunteers were observed against E. coli strains for which AMX-SUL MICs were low (2- to 4-mg/liter) (2 strains) and high (>/=16-mg/liter) (47 strains), respectively.
Bantar
C
C
Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina. bantar@drwebsa.com.ar
Nicola
F
F
Arenoso
H J
HJ
Galas
M
M
Soria
L
L
Dana
D
D
Rossi
A
A
Bianchini
H
H
Jasovich
A
A
D000328:Adult; D000658:Amoxicillin / Q000493:pharmacokinetics* / Q000494:pharmacology; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics* / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics*; D004926:Escherichia coli / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000493:pharmacokinetics*; D013407:Sulbactam / Q000493:pharmacokinetics* / Q000494:pharmacology; D065093:beta-Lactamase Inhibitors
D004791:Enzyme Inhibitors; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D000658:Amoxicillin; D013407:Sulbactam